Last reviewed · How we verify
camrelizumab+apatinib+TMZ
camrelizumab+apatinib+TMZ is a PD-1 inhibitor, VEGFR inhibitor, chemotherapy agent Small molecule drug developed by Peking University Cancer Hospital & Institute. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, PD-L1 positive, Glioblastoma.
Camrelizumab is a PD-1 inhibitor, apatinib is a VEGFR inhibitor, and TMZ is a chemotherapy agent that works by crosslinking DNA.
Camrelizumab is a PD-1 inhibitor, apatinib is a VEGFR inhibitor, and TMZ is a chemotherapy agent that works by crosslinking DNA. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Glioblastoma.
At a glance
| Generic name | camrelizumab+apatinib+TMZ |
|---|---|
| Sponsor | Peking University Cancer Hospital & Institute |
| Drug class | PD-1 inhibitor, VEGFR inhibitor, chemotherapy agent |
| Target | PD-1, VEGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab binds to PD-1, preventing its interaction with PD-L1 and thus activating T cells to attack cancer cells. Apatinib inhibits VEGFR, which is involved in angiogenesis, a process that tumors use to grow their own blood supply. TMZ works by causing DNA crosslinks, which prevent cancer cells from replicating.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Glioblastoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Neutropenia
- Thrombocytopenia
- Leukopenia
Key clinical trials
- Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma (PHASE3)
- Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- camrelizumab+apatinib+TMZ CI brief — competitive landscape report
- camrelizumab+apatinib+TMZ updates RSS · CI watch RSS
- Peking University Cancer Hospital & Institute portfolio CI
Frequently asked questions about camrelizumab+apatinib+TMZ
What is camrelizumab+apatinib+TMZ?
How does camrelizumab+apatinib+TMZ work?
What is camrelizumab+apatinib+TMZ used for?
Who makes camrelizumab+apatinib+TMZ?
What drug class is camrelizumab+apatinib+TMZ in?
What development phase is camrelizumab+apatinib+TMZ in?
What are the side effects of camrelizumab+apatinib+TMZ?
What does camrelizumab+apatinib+TMZ target?
Related
- Drug class: All PD-1 inhibitor, VEGFR inhibitor, chemotherapy agent drugs
- Target: All drugs targeting PD-1, VEGFR
- Manufacturer: Peking University Cancer Hospital & Institute — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic non-small cell lung cancer, PD-L1 positive
- Indication: Drugs for Glioblastoma
- Compare: camrelizumab+apatinib+TMZ vs similar drugs
- Pricing: camrelizumab+apatinib+TMZ cost, discount & access